THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES

Header Logo

Connection

Lucila Garcia-Contreras to Administration, Oral

This is a "connection" page, showing publications Lucila Garcia-Contreras has written about Administration, Oral.
Connection Strength

0.799
  1. Vaginal Suppositories Containing SHetA2 to Treat Cervical Dysplasia: Pharmacokinetics of Daily Doses and Preliminary Safety Profile. J Pharm Sci. 2020 06; 109(6):2000-2008.
    View in: PubMed
    Score: 0.168
  2. Development and validation of a reverse phase HPLC method for SHetA2, a novel anti-cancer drug, in mouse biological samples. J Pharm Biomed Anal. 2019 Jun 05; 170:124-131.
    View in: PubMed
    Score: 0.157
  3. Cryogenic Fabrication of Dry Powders to Enhance the Solubility of a Promising Anticancer Drug, SHetA2, for Oral Administration. AAPS PharmSciTech. 2019 Jan 02; 20(1):20.
    View in: PubMed
    Score: 0.155
  4. Pharmacokinetics of Ethionamide Delivered in Spray-Dried Microparticles to the Lungs of Guinea Pigs. J Pharm Sci. 2017 01; 106(1):331-337.
    View in: PubMed
    Score: 0.134
  5. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicrob Agents Chemother. 2010 Apr; 54(4):1436-42.
    View in: PubMed
    Score: 0.083
  6. Physiologically Based Pharmacokinetic Modeling and Tissue Distribution Characteristics of SHetA2 in Tumor-Bearing Mice. AAPS J. 2020 02 21; 22(2):51.
    View in: PubMed
    Score: 0.042
  7. Development of a dietary formulation of the SHetA2 chemoprevention drug for mice. Invest New Drugs. 2018 08; 36(4):561-570.
    View in: PubMed
    Score: 0.036
  8. Isoxyl assays in plasma. J Pharm Biomed Anal. 2012 Feb 23; 60:1-6.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

THIS IS A DEVELOPMENT VERSION OF PROFILES. PLEASE GO TO THE PRODUCTION ENVIRONMENT FOR UPDATES